$0.04
9.59% today
Nasdaq, Sep 16, 07:48 pm CET
ISIN
US92731L1061
Symbol
VINC

Vincerx Pharma Inc Stock price

$0.04
-0.00 5.68% 1M
-0.79 95.60% 6M
-5.22 99.31% YTD
-13.96 99.74% 1Y
-28.76 99.87% 3Y
-202.16 99.98% 5Y
-186.96 99.98% 10Y
-186.96 99.98% 20Y
Nasdaq, Closing price Mon, Sep 15 2025
-0.00 7.12%
ISIN
US92731L1061
Symbol
VINC
Industry

Key metrics

Basic
Market capitalization
$190.0k
Enterprise Value
$-4.8m
Net debt
positive
Cash
$5.0m
Shares outstanding
2.2m
Valuation (TTM | estimate)
P/E
negative | 0.0
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.1
Financial Health
Equity Ratio
34.0%
Return on Equity
-1,104.0%
ROCE
-1,152.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-31.4m | -
EBIT
$-31.5m | $-28.2m
Net Income
$-30.1m | $-27.4m
Free Cash Flow
$-26.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
26.2% | -
EBIT
26.2% | 10.4%
Net Income
25.1% | 8.8%
Free Cash Flow
35.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-13.0
FCF per Share
$-11.7
Short interest
2.7%
Employees
13
Rev per Employee
$0.0
Show more

Is Vincerx Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Vincerx Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Vincerx Pharma Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Vincerx Pharma Inc forecast:

Buy
86%
Hold
14%

Financial data from Vincerx Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
17% 17%
-
- Research and Development Expense 15 15
47% 47%
-
-31 -31
26% 26%
-
- Depreciation and Amortization 0.05 0.05
0% 0%
-
EBIT (Operating Income) EBIT -31 -31
26% 26%
-
Net Profit -30 -30
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vincerx Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vincerx Pharma Inc Stock News

Neutral
GlobeNewsWire
2 months ago
Revised Potential Distribution Range of $0.03 to $0.07 per share based on current estimates and assumptions
Neutral
GlobeNewsWire
2 months ago
Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal
Neutral
GlobeNewsWire
3 months ago
Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders
More Vincerx Pharma Inc News

Company Profile

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed Hamdy, Raquel Izumi, Tom Thomas, Stuart Hwang, and John Byrd in 2018 and is headquartered in Palo Alto, CA.

Head office United States
CEO Ahmed Hamdy
Employees 13
Founded 2018
Website vincerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today